M
Michael A. Savin
Researcher at Oregon Health & Science University
Publications - 5
Citations - 91
Michael A. Savin is an academic researcher from Oregon Health & Science University. The author has contributed to research in topics: Breast cancer & Retrospective cohort study. The author has an hindex of 4, co-authored 5 publications receiving 34 citations.
Papers
More filters
Journal ArticleDOI
Patient-reported and objectively measured physical function in older breast cancer survivors and cancer-free controls.
TL;DR: Fatigue was the variable most consistently associated with patient-reported physical functioning and age and comorbidities were the variables most consistent associated with objectively measured physical functioning.
Journal ArticleDOI
Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy.
TL;DR: Prior exposure to CDK4/6i therapy did not impact survival outcomes for mHRBC patients taking everolimus plus exemestane, however, there was a trend towards improved OS in the CDK 4/ 6i cohort that should be evaluated in larger cohorts.
Journal ArticleDOI
Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non-Small Cell Lung Cancer Treatment Setting
Casey Mason,Peter G. Ellis,Kathy Lokay,Amanda Barry,Natalie R. Dickson,Ray D. Page,Blase N. Polite,Ravi Salgia,Michael A. Savin,Corey Shamah,Mark A. Socinski +10 more
TL;DR: Clinical pathways can act as a tool to assist oncology practices to promote testing of key biomarkers and subsequent selection of appropriate therapy in patients with metastatic NSCLC.
Journal ArticleDOI
A phase II trial of olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer.
Zahi Mitri,Jacqueline Vuky,Kathleen Kemmer,Michael A. Savin,Swapnil Parmar,Annette Kolodzie,Brett Johnson,Rochelle Williams-Belizaire,Joe W. Gray,Gordon B. Mills +9 more
TL;DR: There is an urgent need to develop novel non chemotherapy treatments for metastatic triple negative breast cancer patients who otherwise have a poor prognosis.
Posted ContentDOI
Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab.
TL;DR: Prior exposure to pertuzumab did not impact survival outcomes in patients receiving T-DM1 for metastatic HER2-positive breast cancer, with none of these measures being statistically different than those estimated for the pertuzumsumab-naïve group.